AspireAssist Surgery in Greater Adelaide

Aspire Assist is a non-surgical and reversible weight loss procedure that allows food contents in your stomach to be aspirated, causing a gastric bypass.

This clinically-proven gastric balloon weight loss procedure is combined with a comprehensive weight loss program by the doctors at The BMI Clinic

How popular is Australian Metabolic & Obesity Surgery? Show reviews, images & opening hours. 9 reviews of Australian Metabolic & Obesity Surgery: "I travelled to Adelaide from remote NT in December 2014 to have a gastric bypass with Dr Bessell. So happy with the surgery, the before and after..."

The AspireAssist is a surgically implanted weight loss device that is used to empty about one-third of the contents of your stomach shortly after you eat.

Weight loss surgery in Australia includes gastric sleeve, gastric bypass, Lap-Band, and the non-surgical gastric balloon and is available in most major cities and towns. In order to qualify, you need to be at least 27kg overweight (BMI of 30+).

The objective of this post-market study was to evaluate long-term safety and efficacy of aspiration therapy (AT) in a clinical setting in five European clinics.

Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future.